Proteomics International Laboratories Adds Three Resolutions to 20 November 2026 AGM for SPP Option Issuances

Anjali Anand

05 November 2026 04:40 PM AEDT

Proteomics International Laboratories Adds Three Resolutions to 20 November 2026 AGM for SPP Option Issuances

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Proteomics International Laboratories Ltd (ASX:PIQ) has issued an amended notice of annual general meeting, adding three new resolutions seeking shareholder approval to issue free attaching options in connection with a Share Purchase Plan, ahead of the meeting scheduled for 20 November 2026.

Key Points

Three additional resolutions — Resolutions 8, 9 and 10 — have been added to the AGM originally noticed on 22 October 2026.
Resolution 8 seeks approval to issue up to 50,000,000 free attaching SPP options to unrelated SPP participants under Listing Rule 7.1.
Resolution 9 seeks approval to issue up to 300,000 free attaching SPP options to Mr Aaron Brinkworth, and Resolution 10 seeks approval to issue up to 300,000 to Mr Paul House, both under Listing Rule 10.11.
The SPP intends to allow eligible shareholders to subscribe for up to $30,000 worth of new fully paid ordinary shares at $0.10 per share, to raise up to $5,000,000 before costs.

Amended AGM Notice and Replacement Proxy Form

The amended notice, filed on 5 November 2026, supplements the original notice of meeting dated 22 October 2026. The AGM is to be held at 9:30 am (AWST) on Friday, 20 November 2026. Shareholders who have already submitted the original proxy form and wish to vote on the three additional resolutions must complete and return the replacement proxy form. Those who have already submitted the original proxy form and do not wish to vote on the additional resolutions do not need to take further action, as their original proxy will be accepted for Resolutions 1 to 7. All other resolutions and explanatory memorandum content from the original notice remain unchanged.

Details of the Three Additional Resolutions

Resolution 8 proposes the issue of up to 50,000,000 free attaching options to unrelated SPP participants under ASX Listing Rule 7.1. Resolution 9 proposes the issue of up to 300,000 free attaching options to Mr Aaron Brinkworth, or his nominee, under Listing Rule 10.11. Resolution 10 proposes the issue of up to 300,000 free attaching options to Mr Paul House, or his nominee, also under Listing Rule 10.11. Voting exclusion statements apply to each of the three resolutions, with the company stating it will disregard votes cast in favour by persons who are expected to participate in or obtain a material benefit from the respective proposed issues.

Share Purchase Plan Background

According to the filing, the company announced on 2 November 2026 that it intended to undertake a Share Purchase Plan offer. Under the SPP, eligible shareholders can subscribe for up to $30,000 worth of new fully paid ordinary shares at an issue price of $0.10 per share, with the offer seeking to raise up to $5,000,000 before costs. The filing states that the shares under the SPP will be issued without shareholder approval under ASX Listing Rule 7.2 (Exception 5). The attaching options subject to Resolutions 8, 9 and 10 are connected to this SPP offer. The amended notice was authorised by the Chair of Proteomics International Laboratories Ltd.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.